Clinical Scorecard: Microbial Profiles in Feces and Sputum Linked to Treatment Outcomes in Patients With Mycobacterium abscessus Pulmonary Disease
At a Glance
Category
Detail
Condition
Mycobacterium abscessus pulmonary disease (PD)
Key Mechanisms
Alterations in fecal and sputum microbiota diversity and composition associated with antibiotic treatment response
Target Population
Adult patients (≥19 years) diagnosed with M abscessus PD undergoing antibiotic therapy
Care Setting
Tertiary referral center with inpatient and outpatient follow-up
Key Highlights
Decreased fecal microbiota diversity at 2 weeks correlates with favorable treatment response.
Baseline fecal abundance of Eubacterium hallii predicts poor response; increased Enterococcus at 2 weeks associates with good response.
High baseline sputum levels of Burkholderia-Caballeronia-Paraburkholderia and Porphyromonas, and decreased Rothia at 2 weeks, link to positive treatment outcomes.
Guideline-Based Recommendations
Diagnosis
Confirm M abscessus infection by molecular methods in patients meeting NTM-PD diagnostic criteria.
Exclude recent antibiotic use (within 2 months) and gastrointestinal comorbidities before enrollment.
Management
Administer combination antibiotic therapy including macrolides, amikacin, imipenem or cefoxitin, and clofazimine guided by in vitro susceptibility.
Provide intensified intravenous antibiotic therapy for approximately 2 weeks at treatment initiation.
Monitoring & Follow-up
Collect sputum and fecal samples at baseline, 2 weeks, and 6 months to assess microbiota changes and treatment response.
Use sputum culture conversion at 2 weeks as an early indicator of treatment response.
Risks
Consider potential alterations in microbiota diversity and composition due to long-term antibiotic use.
Monitor for antibiotic resistance inherent to M abscessus, including macrolide resistance.
Patient & Prescribing Data
Patients with confirmed M abscessus pulmonary disease undergoing antibiotic treatment
Early microbiota signatures in feces and sputum can serve as biomarkers for predicting treatment response, potentially guiding therapy adjustments.
Clinical Best Practices
Perform longitudinal microbiota profiling to identify microbial biomarkers linked with treatment outcomes.
Incorporate microbiota analysis alongside clinical and microbiological assessments to optimize management.
Exclude patients with recent antibiotic exposure or gastrointestinal diseases to avoid confounding microbiota data.
